Bringing greater transparency to "black box" warnings

Clinical Toxicology

Volumn 49, Issue 6, 2011, Pages 448-451

  Buckley, Nick A ^a   Rossi, Simone ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b Australian Medicines Handbook Pty Ltd   (Australia)

Author keywords

Adverse drug reactions; Boxed warnings; Drug policy; Drug regulation; Keywords

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; DROPERIDOL; FLUOXETINE PLUS OLANZAPINE; METHADONE; OLANZAPINE; PLACEBO; PRESCRIPTION DRUG;

AUSTRALIA; CONSUMER; CONSUMER HEALTH INFORMATION; DEATH; DEMENTIA; DRUG CONTRAINDICATION; DRUG LABELING; DRUG SURVEILLANCE PROGRAM; DRUG USE; EDUCATION PROGRAM; ELECTROCARDIOGRAM; GOVERNMENT; HEALTH CARE POLICY; HEALTH PRACTITIONER; HEART FAILURE; HUMAN; MEDICINE; MORTALITY; PACKAGING; PATIENT COUNSELING; PNEUMONIA; PRACTICE GUIDELINE; PRESCRIPTION; PRODUCT SAFETY; PSYCHOSIS; REVIEW; RISK; RISK MANAGEMENT; SUDDEN DEATH; UNITED STATES;

AUSTRALIA; DRUG LABELING; GUIDELINES AS TOPIC; HUMANS; LEGISLATION, DRUG; PATIENT EDUCATION AS TOPIC; PHARMACEUTICAL PREPARATIONS; RISK MANAGEMENT; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 80051749010     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.3109/15563650.2011.593523     Document Type: Review

References (15)

1. Addis A, Sharabi S, Bonati M. Risk classification systems for drug use during pregnancy: Are they a reliable source of information? Drug Saf 2000; 23:245-253.
2. Abelson PH. California' s proposition 65. Science 1987; 237:1553.
3. Generali J. Black Box Rx. blackboxrx.com. 2011. 7-4-2011.
4. Rossi S, ed. The Australian Medicines Handbook (AMH). 12th ed. Adelaide: Australian Medicines Handbook Pty Ltd; 2011.
5. MIMS online-Australian Product Information. https://www. mimsonline.com.au/. 2011. UCB Medica. 7-4-2011.
6. Psychotropic Expert Group and Psychotropic Guidelines. http://etg. tg.com.au/ (6th). 2008. Melbourne, VIC: Therapeutic Guidelines Ltd. 7-4-2011.
7. Moeller KE, Shireman TI, Generali J, Rigler S, Mayorga A. Pharmacy students ' knowledge of black box warnings. Am J Pharm Educ 2010; 74:5.
8. Australian Regulatory Guidelines for Prescription Medicines. http://www.tga.gov.au/pmeds/argpm.pdf. 2004. Therapeutic Goods Administration. 7-4-2011.
9. Medicines Australia Code of Conduct. http://medicinesaustralia. com.au/code-of-conduct/code-of-conduct-current-edition/. 2010. 7-4-2011.
10. van der SH, van Gelder T, Vulto A, Berg M, Aarts J. Understanding handling of drug safety alerts: A simulation study. Int J Med Inform 2010; 79:361-369.
11. Roughead EE, Gilbert AL, Primrose JG. Improving drug use: A case study of events which led to changes in use of fl ucloxacillin in Australia. Soc Sci Med 1999; 48:845-853. (Pubitemid 29089268)
12. Murphy S, Roberts R. " Black box " 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/ risk. J Allergy Clin Immunol 2006; 117:34-39.
13. Guo JJ, Curkendall S, Jones JK, Fife D, Goehring E, She D. Impact of cisapride label changes on codispensing of contraindicated medications. Pharmacoepidemiol Drug Saf 2003; 12: 295-301. (Pubitemid 36700605)
14. Weatherby LB, Nordstrom BL, Fife D, Walker AM. The impact of wording in " Dear doctor " letters and in black box labels. Clin Pharmacol Ther 2002; 72:735-742. (Pubitemid 36021013)
15. Office of Product Review, Therapeutic Goods Administration. 2011. 7-4-2011. (Personal Communication)